Description
Trastuzumab-dttb was first approved as a 150 mg single-dose vial by the FDA in January 2019 across all eligible indications, mainly adjuvant treatment of human epidermal growth factor receptor 2 (HER2)-overexpressing breast cancer, metastatic breast cancer, and metastatic gastric cancer or gastroesophageal junction adenocarcinoma in patients who have not received prior treatment for metastatic disease.
Trastuzumab-dttb is indicated for adjuvant treatment of HER2-overexpressing node-positive or node-negative breast cancer, including:
• As a part of a treatment regimen containing doxorubicin, cyclophosphamide and either paclitaxel or docetaxel.
• With docetaxel and carboplatin.
• As a single agent following multi-modality anthracycline-based therapy.
In addition, trastuzumab-dttb is indicated in combination with paclitaxel for the first-line treatment of HER2-overexpressing metastatic breast cancer and as a single agent for the treatment of HER2-overexpressing breast cancer in patients who have received 1 or more chemotherapy regimens for metastatic disease.
HOW AND WHERE TO BUY trastuzumab-dttb for injection?
You can order trastuzumab-dttb injection through Medvitaz Pharma Solutions under Named Patient Program (NPP). Medvitaz provides patients and physicians access to commercialy approved medicines that are not available to them in their own country. Medvitaz objectives is to make quality medicines available at affordable prices for patients and physicians. To get best retail price/cost of trastuzumab-dttb injection in India, Call 8750295029 or Email [email protected]. FDA approved drugs of Australia, Canada, Delhi, EU, India, New Zealand, Singapore, Switzerland, Turkey & USA.